Suppressing MBD2, a DNA-binding protein, reduced the number of pro-fibrotic macrophages — a type of immune cell involved in pulmonary fibrosis (PF) progression — and lessened lung injury and scarring in a mouse model of PF, a study shows. These findings, based initially on the identification of higher-than-normal MBD2 levels in lung tissue from different types of PF patients, including cases triggered by COVID-19 infection, suggest that blocking MBD2 may be a new potential therapeutic…

You must be logged in to read/download the full post.